Alliance for Pandemic Preparedness
May 11, 2021
Cerebral Venous Thrombosis and Portal Vein Thrombosis a Retrospective Cohort Study of 537913 COVID-19 Cases
Category: Article Summary
Topic: Vaccines and Immunity
Keywords (Tags): clinical characteristics, vaccine
- [Pre-print, not peer-reviewed] Risk of diagnosis for cerebral venous thrombosis (CVT) and portal vein thrombosis (PVT) within 2 weeks of a COVID-19 diagnosis was 6.6-fold higher and 7.4-fold higher, respectively, compared to receiving a COVID-19 mRNA vaccine according to a retrospective study of administrative data in the US. Researchers compared patients with a COVID-19 diagnosis between January 2020 to March 2021 (n=537,913) with age-, sex-, and race-matched vaccinated individuals (n=366,869). Risk of CVT and PVT within 2 weeks of a COVID-19 diagnosis was also 3.8-fold higher and 1.4-fold higher, respectively, when COVID-19 patients were compared with an age-sex-, and race-matched cohort of individuals diagnosed with influenza (n=392,424).
Taquet et al. (May 11, 2021). Cerebral Venous Thrombosis and Portal Vein Thrombosis a Retrospective Cohort Study of 537913 COVID-19 Cases. Pre-print downloaded May 11 from https://doi.org/10.1101/2021.04.27.21256153